Skip to main content

Advertisement

Log in

Detection of response-predicting mutations in the kinase domain of the epidermal growth factor receptor gene in cholangiocarcinomas

  • Original Paper
  • Published:
Journal of Cancer Research and Clinical Oncology Aims and scope Submit manuscript

Abstract

Purpose: Epidermal growth factor receptor (EGFR) signalings have recently been implicated in the genesis and progression of cholangiocarcinomas. Thus, the EGFR kinase inhibitor appears to be promising in the treatment of this cancer. The response-predicting mutations in the tyrosine kinase domain of EGFR gene have recently been detected in non-small cell lung cancers. This study was, therefore, to investigate if these mutations are also found in cholangiocarcinomas. Methods: Twenty-two consecutive cholangiocarcinoma patients who underwent surgical resection were enrolled. Their resected paraffin-embedded cholangiocarcinoma specimens were used for mutation analysis, which was performed by DNA sequencing of exons 18, 19 and 21 in the EGFR gene. Clinical characteristics were compared between each group according to the presence or absence of mutations. Results: Three patients (13.6%) harbored EGFR mutations. All the mutations found were deletions in exon 19. Mutations were more common in intra-hepatic or poorly differentiated tumors. Differences in age, sex, stage at diagnosis and survival were not observed between mutation-positive and -negative patients. Conclusions: This study, for the first time, demonstrates that a subset of cholangiocarcinoma patients has response-predicting EGFR mutations. Therefore, a highly selected application of the EGFR kinase inhibitor would be therapeutically effective in these patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  • Ahrendt SA, Nakeeb A, Pitt HA (2001) Cholangiocarcinoma. Clin Liver Dis 5:191–218

    Article  PubMed  CAS  Google Scholar 

  • Han SW, Kim TY, Hwang PG, Jeong S, Kim J, Choi IS, Oh DY, Kim JH, Kim DW, Chung DH, Im SA, Kim YT, Lee JS, Heo DS, Bang YJ, Kim NK (2005) Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 23(11):2493–2501

    Article  PubMed  CAS  Google Scholar 

  • Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib. N Engl J Med 350:2129–2139

    Article  PubMed  CAS  Google Scholar 

  • Olayioye MA, Neve RM, Lane HA, Hynes NE (2000) The erbB signaling network: receptor heterodimerization in development and cancer. EMBO J 19:3159–3167

    Article  PubMed  CAS  Google Scholar 

  • Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M (2004) EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304:1497–1500

    Article  PubMed  CAS  Google Scholar 

  • Pinkas-Kramarski R, Soussan L, Waterman H, Levkowitz G, Alroy I, Klapper L, Lavi S, Seger R, Ratzkin BJ, Sela M, Yarden Y (1996) Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J 15:2452–2467

    PubMed  CAS  Google Scholar 

  • Rosen CB, Nagorney DM, Wiesner RH, Coffey RJ Jr, LaRusso NF (1991) Cholangiocarcinoma complicating primary sclerosing cholangitis. Ann Surg 213:21–25

    Article  PubMed  CAS  Google Scholar 

  • Suzuki S, Dobashi Y, Sakurai H, Nishikawa K, Hanawa M, Ooi A (2005) Protein overexpression and gene amplification of epidermal growth factor receptor in nonsmall cell lung carcinomas. Cancer 103:1265–1273

    Article  PubMed  CAS  Google Scholar 

  • Tanovic A, Alfaro V (2004) Gefitinib: current status in the treatment of non-small cell lung cancer. Drugs Today (Barc) 40:809–827

    Article  CAS  Google Scholar 

  • Torok N, Gores GJ (2001) Cholangiocarcinoma. Semin Gastrointest Dis 12:125–132

    PubMed  CAS  Google Scholar 

  • Yoon JH, Gores GJ (2003) Diagnosis, staging, and treatment of cholangiocarcinoma. Curr Treat Options Gastroenterol 6:105–112

    Article  PubMed  Google Scholar 

  • Yoon JH, Gwak GY, Lee HS, Bronk SF, Werneburg NW, Gores GJ (2004) Enhanced epidermal growth factor receptor activation in human cholangiocarcinoma cells. J Hepatol 41:808–814

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to J. -H. Yoon.

Additional information

Grant Support: supported by grant No. 03-2005-024 from the Seoul National University Hospital Research Fund.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gwak, G.Y., Yoon, J.H., Shin, C.M. et al. Detection of response-predicting mutations in the kinase domain of the epidermal growth factor receptor gene in cholangiocarcinomas. J Cancer Res Clin Oncol 131, 649–652 (2005). https://doi.org/10.1007/s00432-005-0016-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00432-005-0016-1

Keywords:

Navigation